Additional funding for varenicline for smoking cessation

Additional funding for varenicline for smoking cessation

Hosted Content
Pfizer New Zealand
Varenicline
Now 2X fully funded for 2X 12 weeks every 12 months

Thank you for helping New Zealanders attempt to quit smoking with Varenicline Pfizer (varenicline tartrate). As of 1 October 2019, Varenicline Pfizer is fully funded for one 12 week course every 6 months, doubling the annual access for those wanting to quit smoking.

More funding gives patients increased access to varenicline to help your patients quit smoking.

From 1 October 2019, access to Varenicline Pfizer has been widened in both the community and hospitals by changing the funding restriction to allow one 12 week course to be funded every 6 months.

Increase in funding as of 1 October 2019

Varenicline Pfizer is now 2X fully funded for 2X 12 weeks in a 12 month period, from 1 October 2019.1

For further information please refer to the PHARMAC website.

Help your patients attempt to quit smoking with Varenicline Pfizer.

References

Reference 1. Pharmaceutical Management Agency New Zealand Pharmaceutical Schedule. Update October 2019. Available at pharmac.govt.nz/wwwtrs/ScheduleOnline.php?osq=Varenicline%20tartrate&code=C2234013920. Accessed October 2019.

Mandatories

Varenicline Pfizer is a prescription medicine for the treatment of smoking cessation. Before prescribing please review the data sheet on dosage, contraindications, precautions, interaction and adverse effects. The datasheet is available at www.medsafe.govt.nz or Pfizer New Zealand Ltd (www.pfizer.co.nz) or call 0800 736 363. V10718 ©Pfizer 2019. TAPS NA 11361 PP-CHM-NZL-0109 10/19 essence PF9323